Glythera makes two senior appointments
pharmafile | April 3, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | burns, evetts, glythera
Newcastle-based biotech firm Glythera has appointed Dr Nigel Burns as non-executive director and Ian Evetts as commercial director.
Burns (pictured) brings over 25 years experience in the biopharma and biotech industry to the firm. He has held a series of leadership roles including senior VP of Cambridge Antibody Technology, non-executive director of Navion, chairman of Cell Medica, director and founder of Nascient – and most recently – chief executive and founder of SweetSpot Therapeutics.
Burns says: “I’m very excited to take on this new role at Glythera at such an important time in the company’s development. Glythera is positioned as a key player in the emerging drug therapies market and I’m delighted to join the team and look forward to helping to develop new strategies and drive the future of Glythera’s technologies and therapies.”
Evetts joins Glythera with over 20 years’ experience in the pharma industry. He has a track record of senior strategic and operational roles including managing director at Atebion BDS, strategic advisor at Bionure and business development and portfolio director at AstraZeneca.
Evetts adds: “I am extremely pleased to be involved at this exciting time for the company and I look forward to working with the team as it continues to expand and maximise new opportunities.”
Dr Anthony Baxter, Glythera’s chairman concludes: “We are delighted that Ian and Nigel have joined our team. Their in-depth knowledge of large pharma processes and needs, combined with an undisputed understanding of the relevant biotechnology science will be invaluable to us, particularly as we grow and drive the technologies and therapies business forward.”
